137 related articles for article (PubMed ID: 24130992)
1. Experimental substantiation for the use of mexidol and 3-hydroxypyridine fumarate in chronic myocardial injury.
Zamotaeva MN; Chairkin IN; Inchina VI; Drozdov IA
Bull Exp Biol Med; 2013 Jun; 155(2):212-3. PubMed ID: 24130992
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate.
Zamotaeva MN; Inchina VI; Konorev VV; Kuznetsov YV; Kuz'michev ND
Bull Exp Biol Med; 2018 Jul; 165(3):344-346. PubMed ID: 30006879
[TBL] [Abstract][Full Text] [Related]
3. [The anti-ischemic effects of 3-hydroxypyridine derivatives in cerebrovascular pathology].
Pogorelyĭ VE; Arl't AV; Gaevyĭ MD; Gatsura VV; Smirnov LD
Eksp Klin Farmakol; 1999; 62(5):15-7. PubMed ID: 10572744
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the anxiolytic effects of 3-hydroxypyridine and succinic acid derivatives.
Volchegorskii IA; Miroshnichenko IY; Rassokhina LM; Faizullin RM; Malkin MP; Pryakhina KE; Kalugina AV
Bull Exp Biol Med; 2015 Apr; 158(6):756-61. PubMed ID: 25894772
[TBL] [Abstract][Full Text] [Related]
5. Effects of hydroxypyridine derivatives mexidol and emoxypin on the reparative processes in rabbit eye on the models of corneal epithelial defect and conjunctival ischemia.
Chesnokova NB; Beznos OV; Pavlenko TA; Zabozlaev AA; Pavlova MV
Bull Exp Biol Med; 2015 Jan; 158(3):346-8. PubMed ID: 25573366
[TBL] [Abstract][Full Text] [Related]
6. [Protective effect of 3-hydroxypyridine derivatives in extreme conditions].
Iasnetsov VV
Aviakosm Ekolog Med; 2007; 41(6):5-12. PubMed ID: 18350829
[TBL] [Abstract][Full Text] [Related]
7. [Effect of mexidol on oxidative stress in cerebral variant of hypertensive crisis].
Golikov AP; Golikov PP; Davydov BV; Riabinin VA; Luk'ianov MM; Kalinin AN; Klychnikova EV; Promanenkov VK
Kardiologiia; 2002; 42(3):25-9. PubMed ID: 12494182
[TBL] [Abstract][Full Text] [Related]
8. [Possibilities of «therapeutic retargeting» of 3-hydroxypyridine and succinic acid derivatives due to their dopaminergic action].
Volchegorskii IA; Rassokhina LM; Miroshnichenko IU
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(3):17-26. PubMed ID: 38529859
[TBL] [Abstract][Full Text] [Related]
9. [Antihypoxic effects of various derivatives of 3-hydroxypyridine on isolated rat myocardium].
Luk'ianova LD; Atabaeva RE; Shepeleva SIu
Biull Eksp Biol Med; 1993 Apr; 115(4):366-8. PubMed ID: 8049394
[TBL] [Abstract][Full Text] [Related]
10. Antihypoxic and antinecrotic effect of mexidol in skin ischemia.
Galenko-Yaroshevskii VP; Bagmetova EN; Fil'chukova IA; Sidel'nikov AY; Popkov VA; Gorelashvili AS; Antelava NA; Sukoyan GV
Bull Exp Biol Med; 2005 Feb; 139(2):202-6. PubMed ID: 16027807
[TBL] [Abstract][Full Text] [Related]
11. [ANTIARRHYTHMIC EFFECTS OF 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE HEMISUCCINATE IN COMPARISON TO MEXIDOL.].
Turilova AI; Gan'shina TS; Avdyunina NI; Pyatin BM; Mirzoyan RS
Eksp Klin Farmakol; 2016; 79(7):8-11. PubMed ID: 29782738
[TBL] [Abstract][Full Text] [Related]
12. [Bioenergetic mechanisms of the antihypoxic action of mexidol, the succinate-containing derivative of 3-hydroxypyridine].
Luk'ianova LD; Atabaeva RE; Shepeleva SIu
Biull Eksp Biol Med; 1993 Mar; 115(3):259-60. PubMed ID: 8054612
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of emoxipine and mexidol in patients with chronic disorders of the digestive system and atherosclerosis of the abdominal aorta].
Dolgushina AI
Eksp Klin Farmakol; 2011; 74(12):11-4. PubMed ID: 22379875
[TBL] [Abstract][Full Text] [Related]
14. [The effects of mexidol in pain syndromes].
Danilova ED; Grafova VN; Voronina TA; Reshetniak VK
Eksp Klin Farmakol; 1995; 58(3):17-20. PubMed ID: 7663286
[TBL] [Abstract][Full Text] [Related]
15. [The antioxidant hydroxypyridine-6 as an agent to prevent postresuscitation heart damage].
Dolgikh VT
Patol Fiziol Eksp Ter; 1991; (4):31-3. PubMed ID: 1798649
[TBL] [Abstract][Full Text] [Related]
16. [Gastroprotective properties of mexidol and hypoxen].
Novikov VE; Kriukova NO; Novikov AS
Eksp Klin Farmakol; 2010 May; 73(5):15-8. PubMed ID: 20597364
[TBL] [Abstract][Full Text] [Related]
17. [Metabolic effects of mexidol in complex treatment of chronic brain ischemia].
Demchenko EIu; Kulakova NV; Semiglazova TA; Golovacheva AB; Borodulina EV; Udut VV
Eksp Klin Farmakol; 2008; 71(6):13-5. PubMed ID: 19140508
[TBL] [Abstract][Full Text] [Related]
18. [The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus].
Volchegorskiĭ IA; Mester NV
Klin Med (Mosk); 2007; 85(2):40-5. PubMed ID: 17520888
[TBL] [Abstract][Full Text] [Related]
19. [Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action in alloxan diabetes].
Volchegorskiĭ IA; Rassokhina LM; Miroshnichenko IIu
Eksp Klin Farmakol; 2011; 74(12):27-32. PubMed ID: 22379879
[TBL] [Abstract][Full Text] [Related]
20. [THE INFLUENCE OF MEXIDOL AND 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE HEMISUCCINATE ON LIPOFUSCINE CONTENT IN RAT BRAIN UNDER LOCAL PERMANENT ISCHEMIA CONDITIONS].
Mirzoyan NR; Bagdasaryan NA; Alikhanyan CB; Meliksetyan VS; Bagdasaryan MG; Kukhtarova AM
Eksp Klin Farmakol; 2015; 78(8):3-6. PubMed ID: 26591573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
